Preview Mode Links will not work in preview mode

Jan 29, 2019

For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing novel treatments for patients.

From checkpoint inhibitors to CAR-T cells and model...


Jan 22, 2019

Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery and drug validation.

The use of animal models in oncology has...


Jan 15, 2019

Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing high-throughput biological discoveries and therapeutic development.

High-content imaging has made it possible to...


Jan 8, 2019

Antibiotic resistance is at a crossroad. In the world today, deaths in low income countries from Antimicrobial Resistance (AMR) are predicted to rise dramatically by 2050. We know how to stop this disaster, and some steps are being taken in the right direction. Will these steps be enough?

Antibiotics for Critical...